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Abstract: Racemic mexiletine is a widely used antiarrhythmic agent that blocks sodium channels. The effects of R-(−) and S-(+)
mexiletine stereoisomers on maximum rate of depolarization (V˙max), conduction time, and repolarization have not yet been
investigated in isolated cardiac preparations. We studied the effect of the R-(−) and S-(+) mexiletine on rabbit cardiac action
potential parameters by using the conventionalmicroelectrode technique. Both enantiomers at 20mol/L of therapeutically and
experimentally relevant concentration, signiﬁcantly depressed the V˙max at fast heart rates (BCLs 300–700 ms). R-(−) mexiletine
has more potent inhibitory effect than S-(+) mexiletine. Both R-(−) and S-(+) mexiletine signiﬁcantly inhibited the V˙max of early
extrasystoles measured at 70 ms diastolic interval induced by S1–S2 stimuli. R-(−) mexiletine has more pronounced inhibitory
effect than S-(+) mexiletine. Both R-(−) and S-(+) mexiletine increased signiﬁcantly the ERP/APD90 ratio. The time constant () of
recovery of V˙max was found to be  = 376.0 ± 77.8ms for R-(−)mexiletine and  = 227.1 ± 23.4ms for S-(+)mexiletine, which indicates
a slower offset kinetics for R-(−) mexiletine from sodium channels than that of the S-(+) enantiomer. These data suggest that R-(−)
mexiletine might be a more potent antiarrhythmic agent than S-(+) mexiletine.
Key words: R-(−) mexiletine, S-(+) mexiletine, papillary muscles, V˙max, conduction time, early extrasystoles.
Résumé : La mexilétine racémique est un antiarythmique bloqueur des canaux sodiques largement utilisé. Les effets de la D-(−)
et de la L-(+) mexilétine, des stéréoisomères, sur la vitesse maximale de dépolarisation (V˙max), le temps de conduction et la
repolarisation n’ont pas encore été étudiés dans des préparations de cœur isolé. Nous avons étudié l’effet de la D-(−) et de la L-(+)
mexilétine sur les paramètres du potentiel d’action cardiaque de lapin par la technique demicroélectrode conventionnelle. À des
concentrations pertinentes sur le plan thérapeutique et expérimental de 20 mol/L, nous avons observé avec les deux énan-
tiomères une diminution importante de la V˙max a` des fréquences cardiaques élevées (longueur des cycles de base de 300 a` 700ms).
La D-(−) mexilétine avait un effet inhibiteur plus puissant que la L-(+) mexilétine. La D-(−) et la L-(+) mexilétine entraînaient toutes
deux une inhibitionmarquée de la V˙max pour les extrasystoles précoces mesurées après un intervalle diastolique de 70ms induit
par des stimuli S1–S2. La D-(−) mexilétine avait un effet inhibiteur plus prononcé que la L-(+) mexilétine. La D-(−) et la L-(+)
mexilétine entraînaient toutes deux une augmentation notable du rapport PRE/DPA90 (période réfractaire effective sur durée du
potentiel d’action a` 90 % de la repolarisation). Nous avons observé que la constante de temps () de la récupération de la V˙max était
de 376,0 ± 77,8 ms avec la D-(−) mexilétine et de 227,1 ± 23,4 ms avec la L-(+) mexilétine, ce qui montre que la cinétique de la
diminution de l’effet de la D-(−) mexilétine sur les canaux sodiques est plus lente que celle de l’énantiomère L-(+). Ces données
laissent entendre que la D-(−) mexilétine pourrait être un antiarythmique plus puissant que la L-(+) mexilétine. [Traduit par la
Rédaction]
Mots-clés : D-(−) mexilétine, L-(+) mexilétine, muscles papillaires, V˙max, temps de conduction, extrasystoles précoces.
Introduction
The compound Kö 1173, later denominated mexiletine, exerted
anticonvulsant activity in animal experiments. Since 1972, mexi-
letine has been recognized as an antiarrhythmic agent with char-
acteristics similar to those of lidocaine (Vaughan Williams 1998).
The racemic mexiletine had been classiﬁed as a Class IB antiar-
rhythmic compound (Vaughan Williams 1998), which blocks so-
dium channels in a use-dependent manner with relatively fast
onset and offset kinetics of V˙max block (Campbell 1983; Varró
et al. 1985). The most important advantage of mexiletine over
lidocaine is its good oral availability and longer half-life. Mexile-
tine reduces use-dependently the magnitude of fast sodium cur-
rent (Hering et al. 1983), markedly slows premature conduction
(Hohnloser et al. 1982), suppresses abnormal automacity in Pur-
kinje ﬁbers (Sarkozy andDorian 2007), and shortens the durations
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of action potentials (Arita et al. 1979; Yamaguchi et al. 1979). The
main cardiac indication of mexiletine is the treatment of ventric-
ular arrhythmias (Mason 1993; Singh et al. 1990). At present, there
is a need for available pharmacotherapy to target directly the
ionic basis of most long QT syndromes (LQTS) for the acute termi-
nation of torsades de pointes (TdP) arrhythmia. In a recent article,
it was reported that mexiletine may be an effective treatment
approach to terminate refractory TdP from several acquired
causes of LQTS (Badri et al. 2015). Mexiletine is applied in extra-
cardiac disorders, too. It is widely administered in the therapy of
myotonic disorders (Logigian et al. 2010; Statland et al. 2012), in
Timothy syndrome (Y. Gao et al. 2013), in neuropathies (O’Connor
and Dworkin 2009), and in chronic pain (Park and Moon 2010). A
recent study (Weiss et al. 2016) has provided Class I evidence that
mexiletine has been safe when given daily to patients with amyo-
trophic lateral sclerosis (ALS). Mexiletine therapy has resulted in
large dose-dependent decreases in muscle cramp frequency and
severity. The racemic mexiletine preparations containing both
isomers (R-(−) and S-(+) mexiletine), are used therapeutically. De
Luca et al. demonstrated the stereoselective effects of mexiletine
enantiomers on sodium currents and excitability of skeletal mus-
cle ﬁbers (De Luca et al. 1995). They found that R-(−) isomers were
more potent in sodium current blockade and they highlighted the
probable usefulness of low doses of R-(−) mexiletine in the therapy
of the abnormal hyperexcitability of the myotonic muscles, with
an expectable reduction of unwanted side effects. However, the
detailed cardiac electrophysiological effects of the R-(−) and S-(+)
mexiletine isomers on cardiac ventricular preparations have not
been investigated yet. We examined whether a signiﬁcant differ-
ence exists between the cardiac electrophysiological effects of the 2
enantiomers. Our research group analysed the effects of the enan-
tiomers on action potential parameters in different protocols per-
formed on rabbit right ventricular papillary muscle preparations.
Themain ﬁndings of our study are that the R-(−) mexiletine displays
slower offset kinetics than S-(+) mexiletine, and R-(−) mexiletine dis-
plays a tendency to more potent inhibitory effect than S-(+) mexile-
tine on V˙max, especially at early premature action potentials, i.e., this
enantiomermight exert stronger antiarrhythmic effect especially in
terminating early ventricular extrasystoles.
Materials and methods
Conventional microelectrode technique
All experiments were carried out in compliance with the Guide
for the Care and Use of Laboratory Animals (NIH PublicationNo. 85–23,
revised 1996). The protocols were approved by the Review Board of
the Committee on Animal Research of the University of Szeged
(54/1999 OEj). Youngmale New Zealand rabbits (1000–2000 g) were
euthanized by a blow on the neck and the hearts were removed.
Free right ventricular wall and the right papillary muscles were
prepared and placed into the tissue bath (50 mL) and allowed to
equilibrate for at least 1 hwhile superfused (ﬂow rate 4–5mL/min)
with Locke’s solution containing (in mmol/L): NaCl 120, KCl 4,
CaCl2 2, MgCl2 1, NaHCO3 22, and glucose 11. The pH of this solu-
tion was 7.40 –7.45 when gassed with 95% O2 and 5% CO2 at 37 °C.
During the equilibration period, the ventricular muscle tissues
were stimulated at abasic cycle lengthof 1000ms. Electrical pulses of
2 ms in duration and twice diastolic threshold in intensity (S1) were
delivered to the preparations through bipolar platinum electrodes.
Transmembrane potentials were recorded with the use of glass
capillary microelectrodes ﬁlled with 3 mol/L KCl (tip resistance:
5–15 M). The microelectrodes were coupled through an Ag–AgCl
junction to the input of a high impedance, capacitance-neutralizing
ampliﬁer (Experimetria 2004). Intracellular recordings were dis-
played on a storage oscilloscope (Hitachi V-555) and led to a com-
puter system (APES) designed for online determination of the
following parameters: resting membrane potential, action poten-
tial amplitude, action potential duration at 10%, 25%, 50%, and 90%
repolarization, and the maximum rate of rise of the action poten-
tial upstroke (V˙max ). The following types of stimulation were ap-
plied in the course of the experiments: stimulation with a
constant cycle length of 1000 ms (ventricular muscles); stimula-
tion with different constant cycle lengths ranging from 300 to
5000 ms. To establish the recovery of V˙max, extra test action poten-
tials were elicited by using single test pulses (S2) in a preparation
driven at a basic cycle length of 1000 ms (S1). The S1–S2 interval was
gradually increased from the end of refractory period. The action
potential characteristics of the potentials evoked by each S2 were
determined. The diastolic interval preceding the test action po-
tential was measured from the point corresponding to 90% repo-
larization of the preceding basic action potential to delivery of S2.
The effective refractory period (ERP) of the preparation, deﬁned as
the shortest S1–S2 interval that evoked a propagated action poten-
tial using a stimulus amplitude equal to twice the diastolic thresh-
old intensity, was also determined. Once control measurements
had been obtained, the preparation was superfused either for
45 min with 20 mol/L R-(−) mexiletine or S-(+) mexiletine. The
therapeutically and experimentally relevant concentration of
mexiletine amounts to about 20 mol/L (Paalman et al. 1977).
Same concentration was applied at both stereoisomers. Follow-
ing these periods of exposure, all action potential parameters
were again obtained.
Statistical analysis
Statistical differences were evaluated with Student’s t test and
differences were considered signiﬁcant when p < 0.05. Data are
expressed as mean ± SEM (standard error of the mean).
Results
Effects of mexiletine enantiomers on transmembrane
action potentials
The effects of 20 mol/L R-(−) and S-(+) enantiomers of mexiletine
on actionpotential characteristics in rabbit ventricular andpapillary
muscle preparations are summarized in Table 1, with examples illus-
trated in Fig. 1. At a stimulation cycle length of 1000 ms, the enan-
tiomers did not change ventricular repolarization (Table 1 and
Fig. 1). Neither R-(−) nor S-(+) mexiletine had effects on the action
potentialamplitude, themaximaldiastolicpotential/membraneresting
potential. BothR-(−) andS-(+)mexiletine signiﬁcantly increased theERP/
APD90 ratio (Table 1). Both enantiomers at 20 mol/L concentration
signiﬁcantly depressed the V˙max (Table 1) at a stimulation cycle
Table 1. The electrophysiological effects of R-(−) and S-(+) mexiletine enantiomers in rabbit ventricular papillary
muscle at basic cycle length of 1000 ms.
Parameters MDP (mV) APA (mV) APD90 (ms) APD50 (ms) V˙max (V/s) ERP/APD90
Control −85.1±1.2 (8) 108.7±1.3 (8) 192.2±8.4 (8) 156.0±8.0 (8) 200.2±13.1 (8) 0.953±0.021 (6)
R-(−) Mexiletine 20 mol/L −85.2±1.7 (8) 104.2±2.5 (8) 193.3±6.9 (8) 155.7±7.3 (8) 162.7±7.9* (8) 1.031±0.028* (6)
Control −83.4±1.7 (8) 105.9±1.7 (8) 184.2±11.9 (8) 148.9±13.9 (8) 205.1±12.3 (8) 0.942±0.021 (6)
S-(+) Mexiletine 20 mol/L −83.9±1.1 (8) 106.9±1.8 (8) 198.7±13.1 (8) 161.3±12.4 (8) 167.2±10.5* (8) 0.997±0.015* (6)
Note: Values are means ± SEM with number of observations (i.e., number of preparations obtained from different animals) in
parentheses. MDP, maximum diastolic potential; APA, action potential amplitude; APD90, action potential duration at 90% of repolar-
ization; APD50, action potential duration at 50% of repolarization; V˙max, maximum rising velocity of the action potential upstroke; ERP,
effective refractory period. *p < 0.05.
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length of 1000 ms. The depression of maximal rate of rise of de-
polarization (V˙max) evoked by the stereoisomers (Figs. 2A and 2B)
was strongly dependent upon stimulation frequency (“use depen-
dent”); i.e., as pacing cycle length was decreased (basic cycle
lengths 300–700 ms), the depression of V˙max was increased. There
was no statistically signiﬁcant difference between mexiletine iso-
mers in the degree of inhibition of V˙max (Fig. 2C), although R-(−)
mexiletine demonstrated a somewhat more potent inhibitory
effect. Impulse conduction time (CT), another sodium channel-
mediated parameter, i.e., the time between the stimulus signal
and the action potential upstrokewas also prolonged signiﬁcantly
(Figs. 3A and 3B) by the enantiomers at fast rates. The effects of
mexiletine enantiomers on early premature action potentials fol-
lowing ﬁnal repolarization of the previous basic action potential
(i.e., at a diastolic interval = 70 ms) are summarized in Table 2.
Both R-(−) and S-(+) mexiletine signiﬁcantly depressed the V˙max
(Table 2) of early premature action potentials and R-(−) mexiletine
caused a more potent inhibitory action. At the stimulation cycle
length of 1000ms,mexiletine enantiomers inhibited the recovery of
V˙max (Fig. 4). The time constants for recovery of V˙max in the presence
of 20 mol/L mexiletine enantiomers were  = 376.0 ± 77.8 ms for
R-(−) mexiletine and  = 227.1 ± 23.4 ms for S-(+) mexiletine. The R-(−)
mexiletine seems to display slower offset kinetics, i.e., dissociation
from the sodium channels, and the difference was signiﬁcant
(p < 0.05) between mexiletine isomers in the degree of inhibition of
recovery. The depression was predominant over the range of early
extrasystoles.
Discussion
Possible mechanisms
Mexiletine, a widely used antiarrhythmic drug, exists as a race-
mic mixture, i.e., the available drug preparations contain both
S-(+) and R-(−) enantiomers. It has been extensively studied and
established that racemic mexiletine inhibits V˙max in different car-
diac preparations with relatively fast recovery like lidocaine and,
as such, it was classiﬁed as a Class IB antiarrhythmic drug
(Campbell 1983; Varró et al. 1985). Although the enantiomers, like
with sotalol, may have different effect, so far the cellular cardiac
electrophysiological effect of the S-(+) and R-(−) enantiomers have
never been studied and analysed. Therefore, we have studied the
cardiac electrophysiological effects of mexiletine enantiomers
(20 mol/L) on isolated rabbit ventricular preparations. To estab-
lish whether the R-(−) and S-(+) enantiomers had different proper-
ties, we ﬁrst examined the effect of the stereoisomers on V˙max,
which is the maximum rising velocity of the action potential up-
stroke. V˙max measurements are indicative for INa function (i.e.,
cycle length dependent V˙max block in rabbit ventricular muscles is
Fig. 1. Effect of R-(−) mexiletine (A) and S-(+) mexiletine (B) on action potential waveform of rabbit ventricular muscle at stimulation cycle
length of 1000 ms. The amplitude and time scales for the recording of the ﬁrst derivative of the transmembrane voltage with respect to time
(V˙max) are indicated to the right.
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attributable to the inhibitory effect of mexiletine enantiomers on
the fast Na+ current, but cannot be applied for quantitative esti-
mation of sodium channel availability, which could be underesti-
mated by suchmeasurements (Sheets et al. 1988), because V˙max can
be considered as a nonlinear indicator of the fast inward sodium
current (Cohen et al. 1984). We have found that both the R-(−) and
S-(+) enantiomers of mexiletine at 20 mol/L produced a rate-
dependent inhibition of the V˙max value (Figs. 2A and 2B), but the
inhibition was more pronounced in the case of the R-(−) mexiletine
(Fig. 2C). The stronger depression of V˙max by the R-(−) enantiomer can
be attributed to the slower offset kinetics comparing to its S-(+) en-
antiomer. Indeed, at cycle length range of 400–1000 ms the R-(−)
enantiomer causedmorepronounced V˙max depression than the S-(+)
one. R-(−) mexiletine suppressed V˙max of early premature action
potentials signiﬁcantly (Table 2), and this inhibition was also
more pronounced than that of S-(+) mexiletine. Therefore, we can
speculate that application of medications containing only the
R-(−) mexiletine might decrease the probability of a second con-
ducted impulse occurring at short premature intervals and
thereby reduces the possibility of developing re-entrant tachyar-
rhythmias. De Luca et al. (1995) demonstrated the stereoselective
effects of mexiletine enantiomers (tested at 50 and 100 mol/L) on
sodium currents and excitability of frog skeletal muscle ﬁbers. They
found that R-(−) isomers were more potent in sodium current block-
ade. Inhibition of sodium current has been found to be more
pronounced when the resting membrane potential is partly depo-
larized (Pu et al. 1998), e.g., in ischaemic tissues. Therefore, the
stereoselective effect of mexiletine isomers on V˙max, what we have
found, could be further investigated in future experiments in
cardiac preparations exposed to in vitro ischemia protocols, mim-
icking ischemic heart diseases. We also measured another impor-
tant parameter reﬂecting the availability of sodium channels,
next to V˙max, the impulse conduction time (CT). Before adminis-
tration of each enantiomer, impulse conduction time was inde-
pendent of the stimulation cycle length (300–5000 ms, Fig. 3).
Both enantiomers were capable of exerting marked rate-
dependent impulse CT changes (Fig. 3). The time constant for
recovery of V˙max in the case of R-(−) mexiletine displays slower
offset kinetics than the S-(+) mexiletine (Fig. 4). The mexiletine
stereoisomers did not affect repolarization (Fig. 1) at basic cycle
length of 1000 ms as shown earlier (Vaughan Williams 1998).
Clinical implications
A retrospective study (D. Gao et al. 2013) performed on patients
with an implantable cardioverter deﬁbrillator (ICD) revealed that
when mexiletine was added to amiodarone in case of amiodarone
ineffectiveness, the combination of these drugs reduced ven-
tricular tachycardia and ﬁbrillation events, which might mean ap-
propriate therapy in these patients. In another retrospective study
(Mazzanti et al. 2016), it was recently demonstrated that long-term
treatment withmexiletine shortened the QT interval and resulted
in a major reduction of life-threatening arrhythmic events in
LQT3 patients. Another recent study (Badri et al. 2015) concluded
that in patients with acquired LQT and TdP refractory to conven-
tional treatments, the application of mexiletine may be consid-
ered. Given the possible cellular cardiac electrophysiological
explanations for the latter observations, we should note that
many years ago mexiletine was found to be able to abbreviate the
APD of the M cells and to suppress the development of EADs
(Sicouri et al. 1997) and was also found to be highly effective in
decreasing dispersion of repolarization and preventing TdP in
LQT2 and LQT3 models (Shimizu and Antzelevitch 1997). Turgeon
et al. (1991) demonstrated in their study that R-(−) mexiletine was
more efﬁcient in the prevention of ventricular tachycardia after
coronary ligation in dogs than the S-(+) stereoisomer. Their work
raised the possibility that R-(−) mexiletine may possess stronger
antiarrhythmic characteristics than the opposite enantiomer
(Turgeon et al. 1991). On the basis of De Luca’s (greater potency of
R-(−) mexiletine to inhibit INa) and Turgeon’s and our ﬁndings, it
might be worth examining the effects of the mexiletine stereoiso-
mers, but especially those of the R-(−) mexiletine in different pa-
tient groups, i.e., patients with an implantable cardioverter
Fig. 2. Rate-dependent effect of R-(−) mexiletine (A) and S-(+)
mexiletine (B) on themaximum rate of depolarization (V˙max). Results are
mean ± SEM, *p< 0.05, **p< 0.01 vs. control, n = 8–8. Comparison of the
rate-dependent effects of R-(−) mexiletine and S-(+) mexiletine on the
maximum rate of depolarization (V˙max) (C). Values indicated on ordinate
are calculated by dividing the V˙max valuemeasured in the presence of
either R-(−) or S-(+) mexiletine with its own control V˙max value.
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deﬁbrillator and receiving amiodarone or in LQT3 patients. It has
emerged from experiments performed on Purkinje ﬁbers (Varró
and Lathrop 1990) that combined application of sotalol and mexi-
letine may produce beneﬁcial electrophysiological effects by pos-
sibly exerting intensiﬁed antiarrhythmic efﬁcacy and less
proarrhythmic complications in patients; therefore, itmight be of
value to examine the combined effects of sotalol and R-(−) mexi-
letine in future experiments and clinical studies. Regarding ex-
tracardiac implications, the R-(−) mexiletine could be studied in
patients with myotonic dystrophy. The pharmacokinetic parame-
Fig. 3. Rate-dependent effect of R-(−) mexiletine (A) and S-(+) mexiletine (B) on the conduction time (CT). Results are mean ± SEM, *p < 0.05,
**p < 0.01 vs. control, n = 8–8. The increase in CT in the presence of S-(+) isomer is less than that following exposure to the R-(−) isomer.
Table 2. The electrophysiological effects of R-(−) and S-(+) mexiletine enantiomers on the premature action potential
at 70 ms of diastolic interval in rabbit ventricular papillary muscle.
Parameters MDP (mV) APA (mV) APD90 (ms) APD50 (ms) V˙max (V/s)
Control −83.4±1.5 (7) 109.6±2.1 (7) 204.4±14.5 (7) 165.9±15.7 (7) 208.2±30.2 (7)
R-(−) Mexiletine 20 mol/L −86.0±0.9 (7) 107.9±2.1 (7) 202.5±9.5 (7) 161.5±11.6 (7) 129.7±29.9* (7)
Control −85.0±1.8 (7) 111.3±2.6 (7) 200.7±13.4 (7) 164.2±13.9 (7) 185.6±18.4 (7)
S-(+) Mexiletine 20 mol/L −87.4±1.2 (7) 110.0±2.5 (7) 198.9±18.5 (7) 162.0±14.6 (7) 142.3±13.6* (7)
Note: Values are means ± SEM with number of observations (i.e., number of preparations obtained from different animals) in
parentheses. MDP, maximum diastolic potential; APA, action potential amplitude; APD90, action potential duration at 90% of repolar-
ization; APD90, action potential duration at 90% of repolarization; V˙max, maximum rising velocity of the action potential upstroke;
ERP, effective refractory period. *p < 0.05.
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ters of the enantiomers should always be considered. Kwok et al.
(1995) observed a pharmacokinetic difference betweenmexiletine
stereoisomers in 12 healthy human subjects. In their study (Kwok
et al. 1995), it was described that after oral administration of
200mg racemicmexiletine, themean serum total R-(−)mexiletine
concentrations were signiﬁcantly higher than those for S-(+)mexi-
letine during the ﬁrst 6 h following drug administration. It was
found in a human study (McErlane et al. 1987) involving 5 healthy
subjects that the serum protein binding was signiﬁcantly greater
for R-(−) mexiletine than its antipode and the free fraction of S-(+)
mexiletine was 28.32% ± 1.45% and that of the R-(−) enantiomer
was 19.80% ± 1.49%. Another study (Igwemezie et al. 1989) involv-
ing 5 healthy subjects revealed that the elimination half-life of
S-(+) mexiletine was 11.0 ± 3.80 h, which was signiﬁcantly longer
than that of the R-(−) enantiomer, 9.10 ± 2.90 h. A study in rats
(Mehvar et al. 2002) uncovered non-stereoselective distribution of
the isomers to most tissues with the exception of the liver, where
the concentration of the S-(+) stereoisomer was more than twice of
that of its antipode. This study also established a 2-fold higher tissue/
serum concentration ratio for S-(+) mexiletine enantiomer as com-
pared with the ratio for the R-(–) isomer. The most frequently seen
adverse effects ofmexiletine are often dose related and they affect
mainly the central nervous system. Tremors, nystagmus, blurred
vision, dizziness, drowsiness, confusion, ataxia, paresthesia, dysar-
thria, insomnia, tinnitus, and convulsions are the most common
side effects. Gastrointestinal disturbances can also develop during
mexiletine therapy (Vaughan Williams 1998). Detailed studies are
still needed to establish thepharmacokinetic differencebetween the
2 stereoisomers and its possible therapeutic and toxicological signif-
icance.
Conclusion
Our ﬁndings have particular importance asmexiletine is still an
important drug with a wide range of indications (cardiac arrhyth-
mias, myotonic dystrophy, lidocaine-responsive neonatal epilepsy,
etc.). Slower detachment kinetics of R-(−) mexiletine from the
sodium channels than that of S-(+) mexiletine and pronounced
suppression the V˙max of early extrasystoles by R-(−) mexiletine
might be of therapeutic value. Using lower doses of the probably
more potent R-(−) mexiletine in the therapy of different disease con-
ditions (arrhythmias, abnormal hyperexcitability of the myotonic
muscles, neuropathic pain, ALS), might result in the reduction of
unwanted adverse effects mentioned. To establish, whether the ap-
plication of R-(−) mexiletine alone would result in enhanced antiar-
rhythmic efﬁcacy requires further in vitro and in vivo studies.
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